Compare Citius Pharmaceuticals Inc (CTXR) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nutrien Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: Nutrien Ltd is far larger — about 2445.7× Citius Pharmaceuticals Inc's market cap, and Nutrien Ltd pays a 3.15% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Nutrien Ltd for 59 Days on average.
| CTXR | NTR | |
|---|---|---|
Market Cap | $13.62M | $33.31B |
Volume | 132,438 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $83.94 |
52-Week Low | $0.48 | $53.64 |
Typical Hold Time | 17 Days | 59 Days |
Enterprise Value | $3.79M | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Nutrien (NTR) trades at $69.87, down 0.14% with bearish technical signals despite recent earnings beats. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, though Q2 2026 missed at $2.61. Revenue trends show recovery from $26.0B in 2024 to $26.9B in 2025, with net income margin improving to 8.44%. Recent news highlights mixed sentiment with stock volatility following geopolitical fertilizer developments.
The outlook remains cautiously optimistic with analyst consensus at $76.14 target (8.9% upside) and 60.6% buy ratings. Key opportunities include strong potash demand and cost discipline, while risks involve fertilizer price volatility and competitive pressures from potential Belarus deals. Cash flow trends show consistent operational strength despite negative net flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
